SCHEMBL2349983

SCHEMBL2349983

CC(C)c1ccc(/C=C/C=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.61
KDM4E B2RXH2 3/20 0.55
MAPK1 P28482 2/20 0.55
ALDH1A1 P00352 5/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 4/20 0.52
TRPA1 O75762 1/20 0.52
ALOX5 P09917 1/20 0.52
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
RAB9A P51151 6/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 5/20 0.46
POLB P06746 2/20 0.46
XDH P47989 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833821 1.00 TYR (0.61) TYRKDM4EMAPK1ALDH1A1MAPT
SCHEMBL23918549 0.81 TYR (0.64) TYRKDM4EMAPK1ALDH1A1MAPT
SCHEMBL30075786 0.81 TYR (0.64) TYRKDM4EMAPK1ALDH1A1MAPT
SCHEMBL1310214 0.81 ALDH1A1 (0.75) KDM4EMAPK1ALDH1A1MAPTLMNA
SCHEMBL1310216 0.81 ALDH1A1 (0.75) KDM4EMAPK1ALDH1A1MAPTLMNA
SCHEMBL18269371 0.78 APP (0.67) TYRKDM4EMAPK1ALDH1A1MAPT
SCHEMBL12342387 0.78 KDM4E (0.50) TYRKDM4EMAPK1ALDH1A1MAPT
SCHEMBL21402627 0.78 ALDH1A1 (0.54) TYRKDM4EMAPK1ALDH1A1MAPT
SCHEMBL3718544 0.78 ALDH1A1 (0.59) TYRKDM4EMAPK1ALDH1A1MAPT
Isobutane SCHEMBL19460697 0.78 ALDH1A1 (0.54) KDM4EMAPK1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4356894-A1 SUSTAINABLE PRODUCT WITH MALODORS Beiersdorf AG (DE) 2024-04-24 EP claimed
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO claimed
CN-120682125-B 1-Hydroxy-1-sodium sulfonate structural compound based on cinnamaldehyde derivative, and preparation method and application thereof 中国农业大学 2026-05-15 CN disclosed
EP-4356894-A1 SUSTAINABLE PRODUCT WITH MALODORS Beiersdorf AG (DE) 2024-04-24 EP disclosed
CN-107641086-B Synthetic method of nitroolefin compound 浙江工业大学 2020-05-22 CN disclosed
EP-2257297-B1 COMPOUNDS FOR USE IN THE TREATMENT OF ACNE, SEBORRHOEA AND SEBHORROEIC DERMATITIS, OR FOR REDUCING SEBUM SECRETION MIMETICA PTY LTD (AU) 2017-10-18 EP disclosed
US-20160349635-A1 POSITIVELY CHARGEABLE SINGLE-LAYER ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2016-12-01 US disclosed
US-9436105-B2 Triarylamine derivative and electrophotographic photosensitive member KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2016-09-06 US disclosed
US-9340517-B2 Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor MIMETICA PTY LTD (AU) 2016-05-17 US disclosed
US-20150378268-A1 TRIARYLAMINE DERIVATIVE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER KYOCERA DOCUMENT SOLUTIONS INC. (JP) 2015-12-31 US disclosed
WO-2008030838-A2 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2008-03-13 WO disclosed
WO-2008030843-A1 HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2008-03-13 WO disclosed
EP-0908439-B1 Use of substituted 5-phenyl-pentanols as flavour and perfume HAARMANN & REIMER GMBH (DE) 2003-01-02 EP disclosed
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP disclosed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US disclosed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO disclosed
EP-0908439-A1 Use of substituted 5-phenyl-pentanols as flavour and perfume HAARMANN & REIMER GMBH (DE) 1999-04-14 EP disclosed
US-4996365-A Preparation of alkyl-substituted cinnamaldehydes BASF AKTIENGESELLSCHAFT (DE) 1991-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150378268-A1 TRIARYLAMINE DERIVATIVE AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER NAT1, TYR, PAH TYR 2/4885KDM4E 3006/4885MAPK1 2772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.